Amy L Dzierba

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3126888/publications.pdf

Version: 2024-02-01

414303 567144 3,508 35 15 32 citations h-index g-index papers 35 35 35 6736 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Medicine, 2020, 46, 854-887.	3.9	1,536
2	Surviving Sepsis Campaign: Guidelines on the Management of Critically III Adults with Coronavirus Disease 2019 (COVID-19). Critical Care Medicine, 2020, 48, e440-e469.	0.4	816
3	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Critical Care Medicine, 2021, 49, e219-e234.	0.4	289
4	Managing ICU surge during the COVID-19 crisis: rapid guidelines. Intensive Care Medicine, 2020, 46, 1303-1325.	3.9	281
5	Medicating patients during extracorporeal membrane oxygenation: the evidence is building. Critical Care, 2017, 21, 66.	2.5	84
6	A Review of Inhaled Nitric Oxide and Aerosolized Epoprostenol in Acute Lung Injury or Acute Respiratory Distress Syndrome. Pharmacotherapy, 2014, 34, 279-290.	1.2	64
7	Clinically suspected heparin-induced thrombocytopenia during extracorporeal membrane oxygenation. Journal of Critical Care, 2015, 30, 1190-1194.	1.0	60
8	Effect of Extracorporeal Membrane Oxygenation Use on Sedative Requirements in Patients with Severe Acute Respiratory Distress Syndrome. Pharmacotherapy, 2016, 36, 607-616.	1.2	39
9	The Association of Antibiotic Treatment Regimen and Hospital Mortality in Patients Hospitalized With Legionella Pneumonia. Clinical Infectious Diseases, 2015, 60, e66-e79.	2.9	36
10	Ketamine use in sedation management in patients receiving extracorporeal membrane oxygenation. Intensive Care Medicine, 2016, 42, 1822-1823.	3.9	35
11	Characterizing Critical Care Pharmacy Services Across the United States. , 2021, 3, e0323.		30
12	Drug Class Combination–Associated Acute Kidney Injury. Annals of Pharmacotherapy, 2016, 50, 953-972.	0.9	29
13	Discordance Between Respiratory Drive and Sedation Depth in Critically III Patients Receiving Mechanical Ventilation*. Critical Care Medicine, 2021, 49, 2090-2101.	0.4	24
14	Effect of early mobilization on sedation practices in the neurosciences intensive care unit: A preimplementation and postimplementation evaluation. Journal of Critical Care, 2015, 30, 344-347.	1.0	20
15	Current practice and perceptions regarding pain, agitation and delirium management in patients receiving venovenous extracorporeal membrane oxygenation. Journal of Critical Care, 2019, 53, 98-106.	1.0	19
16	Perceived safety and efficacy of neuromuscular blockers for acute respiratory distress syndrome among medical intensive care unit practitioners: A multicenter survey. Journal of Critical Care, 2017, 38, 278-283.	1.0	17
17	Polymyxin Use Associated With Respiratory Arrest. Chest, 2012, 141, 515-517.	0.4	16
18	Intensive Care Nurses' Knowledge About Use of Neuromuscular Blocking Agents in Patients With Respiratory Failure. American Journal of Critical Care, 2015, 24, 431-439.	0.8	13

#	Article	IF	CITATIONS
19	A Practical Approach to Understanding Acid–Base Abnormalities in Critical Illness. Journal of Pharmacy Practice, 2011, 24, 17-26.	0.5	11
20	Opioid and Benzodiazepine Requirements in Obese Adult Patients Receiving Extracorporeal Membrane Oxygenation. Annals of Pharmacotherapy, 2020, 54, 144-150.	0.9	11
21	Severe Thrombocytopenia in Adults with Severe Acute Respiratory Distress Syndrome: Impact of Extracorporeal Membrane Oxygenation Use. ASAIO Journal, 2016, 62, 710-714.	0.9	10
22	Rethinking the Drug Distribution and Medication Management Model: How a New York City Hospital Pharmacy Department Responded to <scp>COVID</scp> ‶9. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 1471-1479.	0.5	10
23	Chronic Obstructive Pulmonary Disease in the Elderly. Drugs and Aging, 2009, 26, 447-456.	1.3	8
24	Development of best practice recommendations for the safe use of pulmonary hypertension pharmacotherapies using a modified Delphi method. American Journal of Health-System Pharmacy, 2019, 76, 153-165.	0.5	8
25	Moderate to Severe Acute Respiratory Distress Syndrome Management Strategies: A Narrative Review. Journal of Pharmacy Practice, 2019, 32, 347-360.	0.5	8
26	Ventilatory and Pharmacotherapeutic Strategies for Management of Adult Patients on Extracorporeal Life Support. Pharmacotherapy, 2019, 39, 355-368.	1.2	8
27	Chlorhexidine for the prevention of ventilator associated pneumonia in critically ill adults. Journal of Infection Prevention, 2013, 14, 162-169.	0.5	6
28	Tertiary peritonitis: considerations for complex team-based care. European Journal of Trauma and Emergency Surgery, 2022, 48, 811-825.	0.8	6
29	Use of N-Acetylcysteine for Clozapine-Induced Acute Liver Injury: A Case Report and Literature Review. Journal of Pharmacy Practice, 2023, 36, 463-467.	0.5	5
30	Artificial Lithium Toxicity. Journal of Pharmacy Practice, 2015, 28, 479-481.	0.5	3
31	Adverse drug reactions in therapeutic hypothermia after cardiac arrest. Therapeutic Advances in Drug Safety, 2017, 8, 101-111.	1.0	3
32	Increasing Pharmacy Resident Diversity Through Targeted Recruitment Efforts. Journal of Pharmacy Practice, 2023, 36, 743-744.	0.5	2
33	594. Critical Care Medicine, 2015, 43, 150.	0.4	1
34	Contemporary Topics in Critical Care With Evolving Medication Management Considerations. Journal of Pharmacy Practice, 2019, 32, 254-255.	0.5	0
35	A Systematic Approach to a Pharmacy Reading List and Topic Discussions for Residents. Journal of Pharmacy Practice, 2021, 34, 347-349.	0.5	0